The 12 closest competitors and alternatives to Spiderwort among biotech companies — ranked by similarity to what Spiderwort actually does, not by market-cap band.
Subscribe to see Spiderwort’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Spiderwort Biotechnologies Inc. is an Ottawa-based biotechnology innovator specializing in all-natural, plant-based biomaterials designed to support tissue regeneration and repair spinal cord injuries.
Spiderwort is a biotech company headquartered in Canada. It has raised at least $15.7M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $13.2M in July 2022. Xcout tracks 8 named people at Spiderwort, including Scott Jarvis (Chief Financial Officer).
2 more named people on record for Spiderwort, with roles, board committees and tenure — see the full roster →
At least $15.7M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $13.2M | 7 named | |
| — | $2.5M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to Spiderwort by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
CryoStasis is a biotechnology company headquartered in Ottawa, Canada, specializing in the subzero unfrozen bio-preservation of cells, tissues, and organs.
Biotechnology
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Similar biotech company
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Biotechnology
Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.
Biotechnology
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
Similar biotech company
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
Biotechnology
NeXtGen Biologics, Inc. is a medical equipment manufacturing and biotechnology company located in Alachua, Florida, specializing in advanced regenerative medicine.
Biotechnology
Theradaptive, Inc. is a clinical-stage biotechnology company headquartered in Frederick, Maryland, that engineers proteins to bind materials for targeted tissue therapeutics, tissue regeneration, and implantable delivery devices.
Similar biotech company
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Biotechnology
Frontier Bio develops engineered human tissues and vascular grafts to address cardiovascular disease and eliminate the need for organ donors and animal testing. The company provides tissue-engineered blood vessels for vascular grafts and commercializes human-based tissue models and services for preclinical testing.
Similar biotech company
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
Biotechnology
Eterna Regeneratives develops regenerative biomaterials and protein-derived scaffolds designed for mineralisation and tissue regeneration. The company's initial applications focus on oral health and enamel repair through professional consumer dental care formats, as well as bone regeneration for orthopaedic and bone grafting uses.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Spiderwortand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →